



20. Piťha J. Farmakologické ovlivnění nervosvalového přenosu u myastenie gravis. *Remedia* 2004; 14: 485–494.
21. Bashuk RG, Krendell DA. Myasthenia gravis presenting as weakness after magnesium administration. *Muscle and Nerve* 1987; 10: 666.
22. Vohánka S, Mičánková B, Bednařík J. Long-term effect of locally administered botulinum toxin A on neuromuscular transmission: longitudinal single-fiber EMG study. *Movement Disorders* 2007; 22: 35.
23. Itoh H, Shibata K, Nitta S. Sensitivity to vecuronium in seropositive and seronegative patients with myasthenia gravis. *Anesth Analg*. 2002; 95(1): 109–113.
24. Pittinger CB, Eryasa Y, Adamson R. Antibiotik induced paralysis. *Anesth Analg* 1970; 49: 487–501.
25. Parmar B, Francis PJ, Ragge NK. Statins, fibrates and ocular myasthenia. *Lancet* 2002; 31: 717.
26. Ozkul Y. Influence of calcium channel blocker drugs in neuromuscular transmission. *Clin Neurophysiol* 2007; 118(9): 2005–2008.
27. Howard JR. Adverse drug effects on neuromuscular transmission. *Sem Neurol* 1990, 10: 89–102.
28. Scheschonka A, Beuche W. Treatment of postherpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. *Pain* 2003; 104: 423–424.